Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces completion of enrollment in three Phase III trials of Saroglitazar Magnesium in NASH

Posted On: 2019-07-18 11:58:14

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has completed enrollment in EVIDENCES 11, EVIDENCES 111 and EVIDENCES V Phase3 clinical trials of Saroglitazar Mg for treating Non-Alcoholic SteatoHepatitis(NASH). Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico.

Speaking on the development Mr. Pankaj R. Patel, Chairman, Zydus group said, "We are excited about the progress that Saroglitazar Mg has been making in the NASH trials. It is currently being evaluated in over 23 different controlled clinical trials, involving over 3,800 patients. NASH is an area of unmet healthcare need and we are committed to develop this therapy for millions of patients suffering from this deadly disease.

EVIDENCES II is a Phase3 biopsy-driven trial of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic SteatoHepatitis. The primary endpoint will be evaluated by histological improvementof NASH using liver biopsy at the end of 52 weeks.

EVIDENCES III is the prospective, multicenter, randomized, double-blind study of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic Fatty Liver Disease(NAFLD). This trial will measure the change in liver fat content as measuredby non-invasive magnetic resonance imaging (MRI) at week 24. Several other secondary endpoints including Liver stiffness as measured by transient elastography / FibroScan® and Serum alanine aminotransferase (ALT) level will also be evaluated.

EVIDENCES V will evaluate the NASH patients over a period of 18 months, measure the change in the liver fat content by magnetic resonance imaging-derived proton density-fat fraction (MRIPDFF) at Week 24 and evaluatethe liver biopsy driven endpoints of Saroglitazar 4 mg from baseline to Week 76.

Saroglitazar Magnesium was launched in India during September 2013, for the treatment of hypertriglyceridemia and diabetic dyslipidemia in patients with type-2 diabetes not controlled by statins. Saroglitazar Mg has demonstrated beneficial effects in NASH animal models. Saroglitazar Mg favorably affects all components of NASH including steatosis, ballooning, inflammation and fibrosis in NASH models. Saroglitazar Mg has previously demonstrated improvelnent in both liver enzymes along with favorable effects on lipid and glycemic indices in patients with nonalcoholic fatty liver disease in PhaseII clinical trials.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.240.25 as compared to the previous close of Rs. 245.2. The total number of shares traded during the day was 88176 in over 1092 trades.

The stock hit an intraday high of Rs. 247 and intraday low of 238.6. The net turnover during the day was Rs. 21371852.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Automobile Corporation of Goa Ltd board declares interim dividend of Rs. 5 for FY2019-20

Subex Ltd settles pending litigations with ex-directors

Cholamandalam Investment and Finance Company Ltd Q3 consolidated net profit higher at Rs. 389.16 crores

Automobile Corporation of Goa Ltd posts loss of Rs. 1.41 crore in Q3

Bayer Cropscience Ltd calls for board meeting on Feb 3, 2020

EIH Associated Hotels Ltd Q3 net profit at Rs. 20.37 crores

GHCL Ltd Board approves Buy-Back of Equity Shares

HDFC Life Insurance Company Ltd reports consolidated PAT of Rs. 251.09 crores in Q3

PNB Housing Finance Ltd Q3 consolidated net profit declines to Rs. 237.02 crores

APAR Industries Ltd consolidated Q3 net profit at Rs. 36.67 crore

NCLT approves IPCA Laboratories Ltd's resolution plan for Noble Explochem Ltd

Nippon Life India Asset Management Ltd board approves interim dividend of Rs. 3

GHCL Ltd Q3 FY20 consolidated net profit slips to Rs. 96.91 crores

Nippon Life India Asset Management Ltd consolidated Q3 PAT up at Rs. 149.32 crores

JM Financial Ltd reports consolidated profit of Rs. 157.54 crores in Q3

KEC International wins New Orders of Rs. 1,255 crore

GE T&D India wins a SCADA & ADMS project from Jammu & Kashmir Power Development Department to deliver 24/7 power availability

Dishman Carbogen Amcis Ltd Q3 consolidated PAT drops QoQ, YoY

Laurus Labs receives EIR from USFDA for its FDF & API Integrated Facility, Unit 2, Visakhapatnam

PVR Ltd consolidated Q3 net profit at Rs. 36.34 crores

Kirloskar Pneumatic Co. Ltd. board declares interim dividend of Rs. 1 for 2019-20

Keltech Energies Ltd Q3 PAT up at Rs. 3.05 crore

Kirloskar Pneumatic Co. Ltd. Q3 net profit climbs to Rs. 18.17 crores

Oriental Bank of Commerce posts net profit of Rs. 201.66 crores in Q3

GMM Pfaulder Ltd Board declares Third Interim Dividend of Rs. 1

Westlife Development Ltd Q3 consolidated net profit surges to Rs. 14.37 crores

GMM Pfaudler Ltd reports consolidated PAT of Rs. 21.05 crore in Q3

Radico Khaitan Ltd posts Q3 consolidated PAT of Rs. 59.74 crore

Canara Bank reports consolidated net profit of Rs. 406.43 crores in Q3

HT Media Ltd reports consolidated net profit in Q3 FY2020

CARE assigns ratings to MMTC Ltd

Ultratech Cement commissions phase 1 of grinding unit at Bara

Gujarat Intrux Ltd Q3 PAT jumps to Rs. 1.78 crore

D B Corp Ltd Board approves second interim dividend of Rs. 3.50

Frontier Springs Ltd wins award at Rail Analysis India Summit 2020

INDOCO Remedies Ltd consolidated Q3 PAT up at Rs. 9.10 crore

Super Sales India Ltd posts loss of Rs. 0.56 crore in Q3

D B Corp Ltd reports consolidated PAT of Rs. 81.62 crore

Alembic Pharmaceuticals announces USFDA Final Approval for Bimatoprost Ophthalmic Solution, 0.03%

TCS Among Top 3 IoT Service Providers: HFS Research

Shreyas Shipping & Logistics Ltd signs MOA to sell SSL Kutch

Alembic Pharmaceuticals announces USFDA Final Approval for Fenofibrate Tablets USP, 54 mg and 160 mg.

JSW Steel Ltd allots NCDs of Rs. 1000 crore

Dilip Buildcon Ltd inks EPC agreement with UPEIDA for Rs. 1250.01 crore project

Zuari Agro Chemicals Ltd shuts down NPK-A plant due to non-availability of raw material

Mahindra updates on ROXOR litigation

L&T Technology Services joins Qualcomm Smart Cities Accelerator Program

AXISCADES delivers strong Q3 FY20 results - Bagging new contracts and renewals

IIFL Wealth Management Ltd board declares interim dividend of Rs. 10 for FY 2019-20

IIFL Wealth Management Ltd consolidated Q3 net profit at Rs. 74.15 crore







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019